| 3QTI | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | 3QT, CL, GOL | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients., Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy D, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M, McCarthy C, Sellers WR, Hofmann F, Cancer Res. 2011 Jun 22. PMID:21697284 | ||||||||||||||
| Data retrieval |
![]() |
| View 3QTI in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |